Streetbeat News

ADIL

Adial Pharmaceuticals, Inc.

https://www.adialpharma.com

Industry

Biotechnology

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Open

1.02

Mkt cap

6.9M

Volume

193K

High

1.09

P/E Ratio

-0.27

52-wk high

4.17

Low

1.00

Div yield

N/A

52-wk low

0.77

The article lists the stocks that gained and lost the most in Friday's mid-day session. Among the gainers were XORTX Therapeutics, Lipella Pharmaceuticals, and Catalyst Biosciences, while the losers included WEBUY GLOBAL, SolarEdge Technologies, and Processa Pharmaceuticals. Factors influencing these movements include FDA clearances, strategic appointments, acquisitions, and financial results.

Portfolio Pulse from Lisa Levin

October 20, 2023 | 5:45 pm

Several healthcare stocks experienced significant price movements during Friday's intraday session. Notable gainers included Aravive, Lipella Pharmaceuticals, Sagimet Biosciences, Catalyst Biosciences, Redhill Biopharma, and Eiger BioPharmaceuticals. On the other hand, Processa Pharma, Atreca, RVL Pharmaceuticals, Adial Pharmaceuticals, Renovaro Biosciences, and Outlook Therapeutics saw their stock prices decline.

Portfolio Pulse from Benzinga Insights

October 20, 2023 | 5:31 pm

U.S. stocks traded lower with the Nasdaq Composite falling over 1%. Schlumberger N.V. shares fell around 4% after the company released Q3 results, missing revenue consensus. Knight-Swift Transportation Holdings, Lipella Pharmaceuticals, and American Well Corporation shares rose after positive news. SolarEdge Technologies, Adial Pharmaceuticals, and Arcutis Biotherapeutics shares dropped due to negative updates.

Portfolio Pulse from Lisa Levin

October 20, 2023 | 4:00 pm

US stocks traded lower with the Dow Jones index falling around 50 points. American Express Co reported better-than-expected earnings for Q3 with a YoY revenue growth of 12% to $15.38 billion. XORTX Therapeutics, Lipella Pharmaceuticals, and Urgent.ly saw significant stock increases, while SolarEdge Technologies, Adial Pharmaceuticals, and Webuy Global experienced notable drops. SolarEdge issued preliminary Q3 revenue results below estimates and lowered its non-GAAP gross margin guidance. Adial announced a $4 million private placement priced at-the-market under Nasdaq rules. Webuy Global priced a $15.2 million IPO of 3.8 million ordinary shares at $4 per share.

Portfolio Pulse from Lisa Levin

October 20, 2023 | 1:43 pm

Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been awarded a patent for combining its proprietary genetic diagnostic with its lead investigational product AD04, for the treatment of alcohol and opioid use disorders. The patent is seen as a significant milestone in the company's pursuit to provide more effective treatments. The company's shares are up 3.06% at $2.86.

Portfolio Pulse from Vandana Singh

October 19, 2023 | 2:00 pm

Adial Pharmaceuticals has announced that its allowed claims cover the detection of select genotypes for the use of AD04 in treating Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD) patients.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 2:00 pm

Adial Pharmaceuticals has been awarded a Notice of Allowance for a key patent that combines the use of the company's proprietary genetic diagnostic with AD04 to treat alcohol and drug dependence.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 1:59 pm

During Wednesday's pre-market session, several healthcare stocks saw significant movement. Galecto (GLTO), MSP Recovery (LIFW), Cardiff Oncology (CRDF), Intelligent Bio Solutions (INBS), Biohaven (BHVN), and Eledon Pharma (ELDN) all saw increases, with Galecto leading the gainers with a 31.3% increase. On the other hand, Know Labs (KNW), Minerva Surgical (UTRS), Femasys (FEMY), Tharimmune (THAR), DMK Pharmaceuticals (DMK), and Adial Pharmaceuticals (ADIL) all experienced decreases, with Know Labs leading the losers with a 36.5% decrease.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 1:06 pm

Several healthcare stocks experienced significant movement in Tuesday's after-market session. Galecto, Exagen, MSP Recovery, Brainstorm Cell, VYNE Therapeutics, and Freeline Therapeutics saw increases, while Minerva Surgical, Femasys, DMK Pharmaceuticals, Adial Pharmaceuticals, Tharimmune, and SeqLL experienced decreases.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 9:31 pm

Adial Pharmaceuticals has regained compliance with Nasdaq's listing requirements, thereby avoiding potential delisting.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2023 | 12:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.